GlassScriptPhysician profile
Rabin Shrestha
NPI 1164697926
$5,947.84
in general payments reported to CMS, 2019-2025
15 companies · $4,073 in 2025
The $4,073 reported for 2025 was more than what 86% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $441 · 2020: $99.79 · 2021: $268 · 2022: $354 · 2023: $98.45 · 2024: $613 · 2025: $4,073.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,500 · Travel and Lodging: $1,364 · Food and Beverage: $921.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,500.00 |
| Travel and Lodging | $1,364.15 |
| Food and Beverage | $920.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,932.18 | 2022-2025 | |
| Jazz Pharmaceuticals INC. | $485.87 | 2020-2025 | |
| United Therapeutics Corporation | $431.38 | 2021-2025 | Tyvaso, Remodulin, Orenitram |
| Boehringer Ingelheim Pharmaceuticals, INC. | $350.44 | 2019-2023 | Ofev |
| Zoll Respicardia, INC. | $174.30 | 2024 | Remede System |
| Astrazeneca Pharmaceuticals LP | $147.07 | 2021-2024 | Breztri |
| Genentech USA, INC. | $139.93 | 2019 | |
| Harmony Biosciences LLC | $121.10 | 2024 | |
| Gilead Sciences, INC. | $33.79 | 2019 | |
| Ethicon INC. | $27.52 | 2025 | Monarch Platform |
| Edwards Lifesciences Corporation | $24.91 | 2022 | |
| Csl Behring | $24.73 | 2021 | |
| Glaxosmithkline, LLC. | $24.07 | 2019 | |
| Ambu INC. | $16.64 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $13.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rabin Shrestha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.